Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

619 - Survival outcome of weak estrogen /progesterone receptor expression in Her2 negative breast cancer is similar to triple negative breast cancer


20 Dec 2015


Poster presentation 2


Guo-Shiou Liao


Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519


G. Liao1, H. Hsu1, C. Chu2, Z. Hong2, C. Fu2, Y. Chou3, T. Huang4, M. Dai4, J. Yu2

Author affiliations

  • 1 Surgery, Tri-Service General Hospital-Neihu District, 114 - Taipei/TW
  • 2 Surgery, Tri-Service General Hospital-Neihu District, Taipei/TW
  • 3 School Of Public Health, National Defense Medical Center, Taipei/TW
  • 4 Division Of Hematology/oncology, Tri-Service General Hospital-Neihu District, Taipei/TW


Abstract 619


Recent publications have suggested that human epidermal growth factor receptor 2 (HER2)-negative breast cancers with “weak” estrogen receptor (ER)/progesterone receptor (PR) expression levels by immunohistochemical (IHC) analysis were considered as the triple-negative (TN) subtype. This study aimed to evaluate the overall survival (OS), disease-free survival rates (DFS), and disease-specific survival (DSS) based on ER and PR expression levels into one of three groups, ER and PR <1%, ER and PR 1%-20%, and ER or PR >20% by hormone therapy.


Medical records of 3353 breast cancer patients treated from 2006 to 2013 were retrospectively reviewed. Tumor characteristics, type of treatment, OS, DFS and DDS were evaluated among the three patient groups.


Analysis of patient characteristics showed significant differences in age, tumor grade, tumor size, lymph node status, chemotherapy, and hormone therapy among groups. Regarding OS, there were significant differences according to the received hormone therapy in the different groups: ER and PR <1% (P = 0.972), ER and PR 1%-20% (P = 0.264), and ER or PR >20% (P = 0.014). Regarding DFS, there were significant differences in the different groups: ER and PR <1% (P = 0.611), ER and PR 1%-20% (P = 0.847), and ER or PR >20% (P = 0.031). Regarding DDS, there were significant differences in the different groups: ER and PR <1% (P = 0.766), ER and PR 1%-20% (P = 0.629), and ER or PR >20% (P = 0.002).


In HER2 negative breast cancer patient with hormone therapy, ER and PR expression level of 1%-20% has similar survival outcome to the ER and PR expression level of <1% by IHC analysis.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings